empagliflozin

AssetSmall moleculeAlso 10 mg Empagliflozin/1000 mg Metformin XR, 5 mg empagliflozin/850 mg metformin FDC, Empagliflozin + Linagliptin, Empagliflozin + linagliptin low dose

Inhibits renal SGLT2 to reduce glucose reabsorption and lower blood glucose

Stage: Approved
Modality: Small molecule
Target: AMPK signalling
Indications: 17
Trials: 278
Developers: 5

Indications

17

Cardiovascular death
Approvedaccessdata.fda.gov7 Oct 2026
Cardiovascular disease
Approvedaccessdata.fda.gov7 Oct 2026
Chronic heart failure
Approvedema.europa.eu7 Oct 2026

14 more

Targets and what it contains6
Owner and partners5
Trials278
Evidence for its targets7
Competitors12
Aging relevance1
Signals15

Every asset’s record: target, stage, trials and the evidence behind it.

Updated 7 Oct 2026 · 22 sources